Indication: Osteoarthritis:
The use of nabumetone in relieving the signs and symptoms of osteoarthritis (OA) was assessed in double-blind, controlled trials in which 1,047 patients were treated for 6 weeks to 6 months. In these trials, nabumetone in a dose of 1,000 mg/day administered at night was comparable to naproxen 500 mg/day and to aspirin 3,600 mg/day.
Rheumatoid Arthritis:
The use of nabumetone in relieving the signs and symptoms of rheumatoid arthritis (RA) was assessed in double-blind, randomized, controlled trials in which 770 patients were treated for 3 weeks to 6 months. Nabumetone, in a dose of 1,000 mg/day administered at night, was comparable to naproxen 500 mg/day and to aspirin 3,600 mg/day. In controlled clinical trials of rheumatoid arthritis patients, nabumetone has been used in combination with gold, d-penicillamine, and corticosteroids. In clinical trials with osteoarthritis and rheumatoid arthritis patients, most patients responded to nabumetone in doses of 1,000 mg/day administered nightly; total daily dosages up to 2,000 mg were used. In open-labelled studies, 1,490 patients were permitted dosage increases and were followed for approximately 1 year (mode). Twenty percent of patients (n = 294) were withdrawn for lack of effectiveness during the first year of these open-labelled studies. The following table provides patient exposure to doses used in the US clinical trials: Table 2. Clinical Double-Blinded and Open-Labelled Trials of nabumetone in Osteoarthritis and Rheumatoid Arthritis As with other NSAIDs, the lowest dose should be sought for each patient. Patients weighing under 50 kg may be less likely to require dosages beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients'' requirements.
INDICATIONS AND USAGE
Carefully consider the potential benefits and risks of nabumetone tablets, USP and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS Nabumetone tablets, USP are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Indication: Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted.

Indication: Carefully consider the potential benefits and risks of Ibuprofentablets and other treatment options before deciding to use Ibuprofen.Use the lowest effective dose for the shortest duration consistent withindividual patient treatment goals (see WARNINGS Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of Ibuprofen tablets in children have not been conducted.

Indication: Carefully consider the potential benefits and risks of Ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see WARNINGS Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of Ibuprofen tablets in children have not been conducted.

Indication: Meloxicam is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1. 1) Rheumatoid Arthritis (RA) (1. 2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh >=60 kg (1. 3) Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis [ see Clinical Studies (14. Meloxicam is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see Clinical Studies (14. 1) Meloxicam is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weighs >= 60 kg [ see Dosage and Administration ( 2.

Indication: Diclofenac sodium is a non-steroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. ( 1 Diclofenac sodium topical gel was not evaluated for use on joints of the spine, hip, or shoulder. 1 Diclofenac sodium topical gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Diclofenac sodium topical gel has not been evaluated for use on the spine, hip, or shoulder.

Indication: Diclofenac sodium is a non-steroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. ( 1 Diclofenac sodium topical gel was not evaluated for use on joints of the spine, hip, or shoulder. 1 Diclofenac sodium topical gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Diclofenac sodium topical gel has not been evaluated for use on the spine, hip, or shoulder.

Indication: Celecoxib is indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1. 1 Rheumatoid Arthritis (RA) ( 1. 2 Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1. 3 Ankylosing Spondylitis (AS) ( 1. 4 Acute Pain (AP) ( 1. 5 Primary Dysmenorrhea (PD) ( 1. 6 For the management of the signs and symptoms of OA [see Clinical Studies ( 14. 1 For the management of the signs and symptoms of RA [see Clinical Studies ( 14. 2 For the management of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies ( 14. 3 For the management of the signs and symptoms of AS [see Clinical Studies ( 14. 4 For the management of acute pain in adults [see Clinical Studies ( 14. 5 For the management of primary dysmenorrhea [see Clinical Studies ( 14.

Indication: Celecoxib capsules are indicated Celecoxib capsules are a nonsteroidal anti-inflammatory drug indicated for: 1. 6 For the management of the signs and symptoms of OA [ see Clinical Studies ( 14. 1 For the management of the signs and symptoms of RA [ see Clinical Studies ( 14. 2 For the management of the signs and symptoms of JRA in patients 2 years and older [ see Clinical Studies ( 14. 3 For the management of the signs and symptoms of AS [ see Clinical Studies ( 14. 4 For the management of acute pain in adults [ see Clinical Studies ( 14. 5 For the management of primary dysmenorrhea [ see Clinical Studies ( 14.

Indication: Meloxicam Tablets are non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1. 1 Rheumatoid Arthritis (RA) ( 1. 2 Juvenile Rheumatoid Arthritis (JRA) in patients who weigh >= 60 kg ( 1. 3 Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [ see Clinical Studies ( 14. Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies ( 14. Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh >= 60 kg [see Dosage and Administration ( 2.